Addressing Current Questions and Controversies in the Management of Hematologic Cancers — What Clinicians Want to Know | Research To Practice

Addressing Current Questions and Controversies in the Management of Hematologic Cancers — What Clinicians Want to Know

Addressing Current Questions and Controversies in the Management of Hematologic Cancers — What Clinicians Want to Know

Please note that slides and other materials provided are for review only and not to be repurposed or published.

Part 1: Chronic Lymphocytic Leukemia

Friday, December 9, 2022

View Full Slide Presentation

MODULE 1: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL) — Dr Danilov

MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL — Prof Kater

MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Davids

MODULE 4: Selection and Sequencing of Available Therapies for R/R Disease — Dr Thompson

MODULE 5: Promising Investigational Agents and Strategies — Dr Roeker

Part 2: Hodgkin and Non-Hodgkin Lymphoma

Friday, December 9, 2022

View Full Slide Presentation

MODULE 1: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Friedberg

MODULE 2: Follicular Lymphoma (FL) — Dr Nastoupil

MODULE 3: Hodgkin Lymphoma (HL) — Dr Smith

MODULE 4: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma — Dr Maloney

MODULE 5: Mantle Cell Lymphoma (MCL) — Dr Kahl

Part 3: Multiple Myeloma

Friday, December 9, 2022

View Full Slide Presentation

MODULE 1: Front-Line Treatment of Multiple Myeloma (MM) — Dr Orlowski

MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Fonseca

MODULE 3: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje

MODULE 4: Bispecific Antibodies in the Treatment of MM — Dr Berdeja

MODULE 5: Other Investigational Novel Agents for MM — Dr Lonial